Trials
2 active
2 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Allogeneic CAR-NK cells engineered with a dual-recognition CAR targeting MSLN and MUC1. Administered as an IV infusion on Day 0 (dose level dependent).”In the company’s words, NCT07480928 on ClinicalTrials.gov
- Tested for
- Pancreatic Ductal Adenocarcinoma (PDAC) (2 trials), Unresectable Locally Advanced or Metastatic Disease, Unresectable Locally Advanced, Metastatic Disease
- Main trialPhase 1/2
- “This example study evaluates the safety, tolerability, and preliminary anti-tumor activity of investigational, dual-targeting chimeric antigen receptor natural killer (CAR-NK) cell products for patients with advanced pancreatic ductal adenocarcinoma (PDAC). Participants are assigned to one of two biomarker-defined cohorts based on tumor antigen expression: (A) Mesothelin (MSLN) and/or MUC1, or (B) Claudin 18.2 (CLDN18.2) and/or MUC1. The study uses a dose-escalation followed by dose-expansion design to define a recommended Phase 2 dose (RP2D) and to estimate response rates in each cohort.”In the company’s words, NCT07480928 on ClinicalTrials.gov
Other drugs for Pancreatic Ductal Adenocarcinoma (PDAC)
- CAM2029Camurus AB · Phase 3
- Immuncell-LCGC Cell Corporation · Phase 3
- RYZ101RayzeBio, Inc. · Phase 3
- XNW28012Evopoint Biosciences Inc. · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- DaraxonrasibRevolution Medicines · Phase 3
Coming up2
- 14 Feb 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 14 Apr 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 14 Feb 2027 | Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma | |
| Phase 1/2Recruiting | 14 Apr 2027 | Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026